Assess whether a CMC change is a comparability or a new product (27f3b1)

Situation

The desk packet is disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module. Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT has to name A CMC change is a comparability or A new product for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMC change is a comparability / A new product using disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Labeling negotiator can defend A CMC change is a comparability from disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge.
• Labeling negotiator cannot defend A CMC change is a comparability from disproportionate reporting signal workbook; A new product is what the extract actually supports after a CMO 483 that maps to the NDA CMC module.
• A CMO 483 that maps to the NDA CMC module never reached the population in disproportionate reporting signal workbook — reopen intake, do not close a CMC change is.
• Two facts in disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module conflict for labeling negotiator; hold this Clinical and Evidence Strategy file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether disproportionate reporting signal workbook supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a CMO 483 that maps to the NDA CMC module and write the one fact that would move a CMC change is for labeling negotiator.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module). If disproportionate reporting signal workbook cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. If disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module cannot support A CMC change is a comparability versus A new product on this Pharma & Life Sciences Clinical and Evidence Strategy close, labeling negotiator must state the unresolved clinical or safety evidence requirement explicitly.